Blood-brain barrier permeability to morphine-6-glucuronide is markedly reduced compared with morphine

Drug Metabolism and Disposition

Volumn 25, Issue 6, 1997, Pages 768-771

  Wu, Dafang ^b   Kang, Young Sook ^b   Bickel, Ulrich ^b   Pardridge, William M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

MORPHINE; MORPHINE 6 GLUCURONIDE;

ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; DRUG PENETRATION; DRUG SOLUBILITY; DRUG UPTAKE; INTRAVENOUS DRUG ADMINISTRATION; LIPID SOLUBILITY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TISSUE DISTRIBUTION;

ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BLOOD-BRAIN BARRIER; BRAIN; HALF-LIFE; MALE; METABOLIC CLEARANCE RATE; MORPHINE; MORPHINE DERIVATIVES; NALOXONE; NARCOTIC ANTAGONISTS; NARCOTICS; PAIN THRESHOLD; RATS; RATS, SPRAGUE-DAWLEY;

ANIMALIA; STAPHYLOCOCCUS PHAGE 187;

EID: 0004844581     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. K. Shimomura, O. Kamata, S. Ueki, S. Ida, K. Oguri, H. Yoshimura, and H. Tsukamoto: Analgesic effect of morphine glucuronides. Tohoku J. Exp. Med. 105, 45 (1971).
2. D. Paul, K. M. Standifer, C. E. Inturrisi, and G. W. Pasternak: Pharmacological characterization of morphine-6-beta-glucuronide, a very potent morphine metabolite. J. Pharmacol. Exp. Ther. 251, 477-483 (1989).
3. B. Frances, R. Gout, B. Monsarrat, J. Cros, and J.-M. Zajac: Further evidence that morphine-6-glucuronide is a more potent opioid agonist than morphine. J. Pharmacol. Exp. Ther. 262, 25-31 (1992).
4. M. Barjavel, P. Sandouk, M. Plotkine, and J.-M. Scherrmann: Morphine and morphine metabolite kinetics in the rat brain as assessed by transcortical microdialysis. Life Sci. 55, 1301-1308 (1994).
5. T. A. Aasmundstad, J. Morg, and R. E. Paleness: Distribution of morphine 6-glucuronide and morphine across the blood-brain barrier in awake, freely moving rats investigated by in vivo microdialysis sampling. J. Pharmacol. Exp. Ther. 275, 435-441 (1995).
6. F. Stain, M. J. Barjavel, P. Sandouk, M. Plotkine, J.-M. Scherrmann, and H. N. Bhargava: Analgesic response and plasma and brain extracellular fluid pharmacokinetics of morphine and morphine-6-beta-D-glucuronide in the rat. J. Pharmacol. Exp. Ther. 274, 852-857 (1995).
7. S. Bjorkman, J. Akeson, M. Heifer, A. Fyge, and L. L. Gustafsson: Cerebral uptake of morphine in the pig calculated from arterio-venous plasma concentration gradients: an alternative to tissue microdialysis. Life Sci. 57, 2335-2345 (1995).
8. U. Bickel, O. Schumacher, Y.-S. Kang, and K. Voigt: Poor permeability of morphine-3-glucuronide and morphine-6-glucuronide through the blood-brain barrier in the rat. J. Pharmacol. Exp. Ther. 278, 107-113 (1996).
9. M. W. H. Coughtrie, B. Ask, A. Rane, B. Burchell, and R. Hume: The enantioselective glucuronidation of morphine in rats and humans. Biochem. Pharmacol., 38, 3273-3280 (1989).
10. W. M. Pardridge and L. J. Mietus: Transport of steroid hormones through the rat blood-brain barrier. J. Clin. Invest. 64, 145-154 (1979).
11. D. R. Brown, M. J. Robertson, and L. I. Goldberg: Reversal of morphine-induced catalepsy in the rat by narcotic antagonists and their quarternary derivatives. Neuropharmacology 22, 317-321 (1983).
12. R. W. Milne, R. L. Nation, G. D. Reynolds, A. A. Somogyi, and J. T. van Crugten: High-performance liquid chromatographic determination of morphine and its 3- and 6-glucuronide metabolites: improvements to the method and application to stability studies. J. Chromatogr. (Biomed. Appl.) 565, 457-464 (1991).
13. Y.-S. Kang and W. M. Pardridge: Use of neutral-avidin improves pharmacokinetics and brain delivery of biotin bound to an avidin-monoclonal antibody conjugate. J. Pharmacol. Exp. Ther. 269, 344-350 (1994).
14. W. M. Pardridge, Y.-S. Kang, and J. L. Buciak: Transport of human recombinant brain-derived neurotrophic factor (BDNF) through the rat blood-brain barrier in vivo using vector-mediated peptide drug delivery. Pharm. Res. 11, 738-746 (1994).
15. A. Samii, U. Bickel, U. Stroth, and W. M. Pardridge: Blood-brain barrier transport of neuropeptides: analysis with a metabolically stable dermorphine analogue. Am. J. Physiol. 267, E124-E131 (1994).
16. M. H. Hanna, S. J. Peat, A. A. Knibb, and C. Fung: Disposition of morphine-6-glucuronide and morphine in healthy volunteers. Br. J. Anaesth. 66, 103-107 (1991).
17. R. W. Milne, R. L. Nation, and A. A. Somogyi: The disposition of morphine and its 3- and 6-glucuronide metabolites in humans and animals, and the importance of the metabolites to the pharmacological effects of morphine. Drug Metab. Rev. 38, 345-472 (1996).
18. P.-A. Carrupt, B. Testa, A. Bechalany, N. E. Tayer, P. Descas, and D. Perrissoud: Morphine-6-glucuronide and morphine-3-glucuronide as molecular chameleons with unexpected lipophilicity. J. Med. Chem. 34, 1272-1275 (1991).
19. R. Poyhia and T. Seppala: Liposolubility and protein binding of oxycodone in vitro. Pharmacol Toxicol. 74, 23-27 (1991).
20. R. W. Milne, R. L. Nation, A. A. Somogyi, F. Bochner, and W. M. Griggs: The influence of renal function on the renal clearance of morphine and its glucuronide metabolites in intensive-care patients. Br. J. Clin. Pharmacol. 34, 53-59 (1992).
21. M. E. Morgan, D. Singhal, and B. D. Anderson: Quantitative assessment of blood-brain barrier damage during microdialysis. J. Pharmacol. Exp. Ther. 277, 1167-1176 (1996).
22. W. H. Oldendorf, S. Hyman, L. Braun, and S. Z. Oldendorf: Blood-brain barrier penetration of morphine, codeine, heroin, and methadone after carotid injection. Science 178, 984-986 (1972).
23. M. M. Hertz and T. G. Bolwig: Blood-brain barrier studies in the rat: an indicator dilution technique with tracer sodium as an internal standard for estimation of extracerebral contamination. Brain Res. 107, 333-343 (1976).
24. G. W. Pasternak, R. J. Bodnar, J. A. Clark, and C. E. Inturrisi: Morphine-6-glucuronide: a potent mu agonist. Life Sci 41, 2845-2849 (1987).
25. P. Thompson, D. Hucks, L. McLoughlin, A. Grossman, L. Rees, and M. Slevin: Comparative opiate receptor affinities of morphine and its active metabolite morphine 6-glucuronide. Br. J. Cancer 62, 484 (1990).
26. G. C. Rossi, Y.-X. Pan, G. P. Brown, and G. W. Pasternak: Antisense mapping the MOR-1 opioid receptor: evidence for alternative splicing and a novel morphine-6-β-glucuronide receptor. FEBS Lett. 369, 192-196 (1995).